En esta entrevista Nadia Badri aborda la importancia de la colaboración entre la industria farmacéutica y las Administraciones para poder impulsar la innovación y sostenibilidad del SNS. Destaca en este sentido los Acuerdos de Riesgo Compartido como una herramienta que facilite el acceso de los tratamientos a los pacientes.
El Modelo de innovación de PharmaMar se basa en la fuente de la que extraen ideas y soluciones, el mar. Este concepto de “Blue Biotechnology” se fundamenta en identificar moléculas sintetizadas por microorganismos marinos, siendo esta vía una clara oportunidad para abordar nuevas terapias para el cáncer. Una vez identificada la posible droga, ésta se sintetiza de forma química en el laboratorio para preservar y conservar la vida marina.
Los principales retos para PharmaMar son anticiparse a las tendencias del mercado oncológico, y adelantarse a los competidores desarrollando estrategias que mejoren el acceso de los tratamientos a los pacientes así como la optimización de costes.
“The relationship between payers and the pharmaceutical industry is changing. Both parties know they need to reach agreements to support
both innovation and sustainability. In Spain, they are already moving forward in this direction, as exemplified by the Risk Sharing Agreements” .
PharmaMar has become a fully integrated company from R&D to the market, and this has been possible, in part, because of our business model. One of our differentiating characteristics is the root of our research and our products, the sea. Another feature is that even though we are a biotech, we
are a profitable company. This has been the result of successfully forming a sales force all over Europe that commercializes our first drug approved in the EU, YONDELIS®, and establishing important partnerships worldwide. We also have a robust pipeline of investigational drugs that are showing
remarkable clinical results in different tumor types that are currently under investigation.
An efficient and smooth-running organization that aims to optimize every process has made this possible.
“We are leaders in the development of anticancer drugs of marine origin, because our drug discovery process starts the moment our marine scientists
identify the new species that will allow us to identify novel molecules”
“It will be important for us to anticipate future trends in the oncology market and better understand the approaches of our competitors to be up-to-speed on developing strategies to improve patient access and optimize costs”
As a medium-size biopharmaceutical company, we have the flexibility to establish well-developed strategies without delay to meet the demands of a competitive market. In contrast to big pharma, we can exploit this capacity to adapt to unexpected changes and tackle challenges that suddenly arise, leveraging the streamlined communication between departments. This sense of teamwork allows the Company to cope with various challenges in due course and to implement the same strategy across different areas.
...
